These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 1978494

  • 1. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
    Farde L, von Bahr C.
    Acta Psychiatr Scand Suppl; 1990; 358():67-71. PubMed ID: 1978494
    [Abstract] [Full Text] [Related]

  • 2. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
    Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G.
    Biol Psychiatry; 1993 Feb 15; 33(4):227-35. PubMed ID: 8097114
    [Abstract] [Full Text] [Related]

  • 3. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K.
    Acta Psychiatr Scand Suppl; 1990 Feb 15; 358():27-36. PubMed ID: 1978484
    [Abstract] [Full Text] [Related]

  • 4. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA, Farde L, Nordström AL, Sedvall G.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Feb 15; 14(5):759-67. PubMed ID: 1981395
    [Abstract] [Full Text] [Related]

  • 5. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L.
    Am J Psychiatry; 1999 Jun 15; 156(6):869-75. PubMed ID: 10360125
    [Abstract] [Full Text] [Related]

  • 6. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.
    Köhler C, Radesäter AC, Karlsson-Boethius G, Bryske B, Widman M.
    J Neural Transm Gen Sect; 1992 Jun 15; 87(1):49-62. PubMed ID: 1531593
    [Abstract] [Full Text] [Related]

  • 7. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S, Farde L, Halldin C.
    Arch Gen Psychiatry; 1997 Oct 15; 54(10):953-8. PubMed ID: 9337776
    [Abstract] [Full Text] [Related]

  • 8. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF.
    Neuropsychopharmacology; 2002 Aug 15; 27(2):248-59. PubMed ID: 12093598
    [Abstract] [Full Text] [Related]

  • 9. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
    Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T.
    Psychopharmacology (Berl); 2008 Apr 15; 197(2):229-35. PubMed ID: 18058087
    [Abstract] [Full Text] [Related]

  • 10. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB.
    J Clin Psychiatry; 2002 Nov 15; 63(11):992-7. PubMed ID: 12444812
    [Abstract] [Full Text] [Related]

  • 11. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
    Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B.
    Psychopharmacology (Berl); 1993 Nov 15; 110(3):265-72. PubMed ID: 7530376
    [Abstract] [Full Text] [Related]

  • 12. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients.
    Nyberg S, Farde L, Halldin C.
    Psychiatry Res; 1996 Oct 07; 67(3):163-71. PubMed ID: 8912956
    [Abstract] [Full Text] [Related]

  • 13. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
    Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C.
    Psychopharmacology (Berl); 1997 Oct 07; 133(4):396-404. PubMed ID: 9372541
    [Abstract] [Full Text] [Related]

  • 14. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET.
    Wiesel FA, Farde L, Halldin C.
    Acta Psychiatr Scand Suppl; 1989 Oct 07; 352():30-4. PubMed ID: 2573239
    [Abstract] [Full Text] [Related]

  • 15. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R.
    Psychopharmacology (Berl); 1998 Jan 07; 135(2):119-26. PubMed ID: 9497016
    [Abstract] [Full Text] [Related]

  • 16. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
    Nordström AL, Farde L.
    J Clin Psychopharmacol; 1998 Aug 07; 18(4):305-10. PubMed ID: 9690696
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.